Table 1.
Study characteristics
| References | Year | Author | Design | DOAC/VKA | CHADS2 (mean ± SD) (median (IQR)) | No. of Patients | No. of Interruptions |
|---|---|---|---|---|---|---|---|
| 20 | 2012 | Healey | RCT |
Dabigatran 150 Dabigatran 110 Warfarin |
2.1 ± 1.1 2.1 ± 1.1 2.1 ± 1.1 |
4591 | 4591 |
| 21 | 2014 | Sherwood | RCT |
Rivaroxaban Warfarin |
3.40 ± 0.95 3.42 ± 0.96 |
2130 | 2980 |
| 22 | 2014 | Garcia | RCT |
Apixaban Warfarin |
2.1 ± 1.1 2.1 ± 1.1 |
3930 | 5741 |
| 23 | 2015 | Douketis | RCT |
Edoxaban 60 Edoxaban 30 Warfarin |
2.8 ± 0.9 2.9 ± 0.9 2.8 ± 1.0 |
3116 | 3116 |
| 24 | 2015 | Schulman | Prospective Cohort | Dabigatran/‐ | – | 531 | 531 |
| 25 | 2014 | Kosiuk | Prospective Cohort | Dabigatran/‐ | 4 (3‐5) | 85 | 85 |
| 26 | 2014 | Terekhov | Prospective Cohort | Dabigatran/‐ | – | 16 | 16 |
| 27 | 2016 | Madan | Retrospective Cohort | Dabigatran/‐ | – | 47 | 47 |
DOAC, Direct Oral Anticoagulant; RCT, Randomized Controlled Trial; VKA, Vitamin K Antagonist.